Birgegård G, Wide L, Simonsson B
Department of Internal Medicine, University Hospital, Uppsala, Sweden.
Br J Haematol. 1989 Jul;72(3):462-6. doi: 10.1111/j.1365-2141.1989.tb07733.x.
Serum erythropoietin (Epo) was measured in 23 patients before, during and after intensive cytostatic treatment courses for acute leukaemia or before bone marrow transplantation. A marked increase was seen in all patients, starting 1 or 2 d after initiation of treatment. A peak was reached after about 7 d, at levels as high as 1450 IU/l, after which Epo fell rapidly, even in patients who were anaemic at that time. In 13 of the patients there was no fall in Hb level that could explain the increase in Epo. The increase was too large to be explained by an altered Epo metabolism or marrow utilization. Cytostatic drugs cause an increase in Epo production not mediated through anaemia, possibly initiated by a cytostatic effect on the kidneys or by an unknown stimulatory factor, responsive to bone marrow inhibition.
对23例急性白血病患者在强化细胞抑制治疗疗程期间及之后或骨髓移植前、中、后测定血清促红细胞生成素(Epo)。所有患者均出现显著升高,在治疗开始后1或2天开始。约7天后达到峰值,高达1450 IU/l,此后Epo迅速下降,即使是当时贫血的患者。13例患者的血红蛋白水平没有下降,无法解释Epo的升高。这种升高幅度太大,无法用Epo代谢改变或骨髓利用情况来解释。细胞抑制药物导致Epo产生增加,并非由贫血介导,可能是由对肾脏的细胞抑制作用或未知的刺激因子引发,该因子对骨髓抑制有反应。